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Changes in cell adhesion properties are hallmarks of the processes
of tumorigenesis and metastasis. Indeed, normal cells depend on
interaction with the extracellular matrix for growth, and the loss of
this dependence is the aspect of cell transformation in vitro most
closely correlated with tumorigenicity (Freedman and Shin, 1974).
The integrin family of cell surface receptors mediates attachment
of cells to the extracellular matrix (reviewed in Hynes, 1992;
Juliano, 1994), and alterations in integrin binding or signaling
properties are being increasingly recognized as important in
tumorigenesis (Ruoslahti, 1997; Clezardin, 1998).
The secreted phosphoprotein osteopontin (OPN), ubiquitously
expressed in body fluids, binds with high affinity to integrins of
the av class (Liaw et al, 1995; Hu et al, 1995a; 1995b) including
avb3, avb1, and a vb5. Interaction of the protein with several b1
integrins has also been reported recently (Smith et al, 1996; Denda
et al, 1998; Bayless et al, 1998), as well as with a non-integrin cell
surface receptor, CD-44 (Weber et al, 1996; Katagiri et al, 1999).
In vivo, OPN expression is increased in a variety of pathologies
(reviewed in Rittling and Denhardt, 1999), where it may act as a
macrophage chemoattractant (Singh et al, 1990; Giachelli et al,
1998), or as a repressor of induced nitric oxide synthase (iNOS)
levels (Hwang et al, 1994; Rollo et al, 1996): this activity may be
especially relevant in pathologies involving ischaemia, in which
nitric oxide (NO) production is thought to be an important medi-
ator of tissue damage (Goligorsky et al, 1997; Noiri et al, 1999). In
vitro, the protein has cell attachment activity (Somerman et al,
1987; Chambers et al, 1993; Senger et al, 1994), and stimulates
migration of several cell types, including endothelial cells (Senger
et al, 1996) and smooth muscle cells (Liaw et al, 1995).
There is extensive evidence derived from observations made
both in vitro and in vivo linking elevated osteopontin expression
and transformation/tumorigenesis. The protein was originally
characterized as transformation-associated due to its increased
expression in transformed cell lines (Senger et al, 1983): indeed, a
wide variety of transformed cells in culture express much higher
levels of the protein than their normal counterparts (Senger et al,
1988). These observations have been extended in that among
transformed cells, the highest levels of expression were found in
the most metastatic cell lines (Chambers et al, 1992a). OPN is
particularly highly expressed in ras-transformed cells (Chambers
et al, 1990), and ras has a direct effect on OPN transcription, via a
ras-stimulated transcription factor that enhances transcription of
the OPN gene (Guo et al, 1995). OPN is also highly expressed in
tumors in vivo. In papillomas and carcinomas induced by
DMBA/TPA initiation/promotion in mouse skin, OPN expression
levels correlate with tumor stage (Craig et al, 1990). In mammary
tumors arising in transgenic mice expressing ras and/or myc
specifically in mammary gland, OPN expression is dramatically
increased at both the message and protein level over levels in the
corresponding normal mammary gland (Rittling and Novick,
1997). OPN is typically overexpressed in human tumors (Brown et
al, 1994; Bellahcène and Castronovo, 1995; Hirota et al, 1995;
Tuck et al, 1998), although the source of the protein in these
malignancies can be either tumor cells or tumor-associated
macrophages (Brown et al, 1994; Casson et al, 1997)
A series of functional studies links OPN causally to tumori-
genesis. Experiments in which OPN mRNA level was reduced in
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already transformed cells indicated that the protein is important in
transformation. Thus, transfection of different antisense OPN
constructs or ribozymes into transformed, tumorigenic cells
resulted in impaired anchorage-independent growth, as well as
tumor-forming ability in vivo (Gardner et al, 1994; Su et al, 1995;
Feng et al, 1995; Behrend et al, 1994). Even more compelling are
results showing that transfection of OPN expression constructs
into cells producing benign tumors converts them to a malignant
phenotype (Oates et al, 1996; Chen et al, 1997).
In order to more clearly define the role OPN plays in transfor-
mation in vitro and tumorigenesis in vivo, we have examined these
processes in cells derived from mice with a targeted disruption of
the OPN gene (Rittling et al, 1998). The results presented here
indicate that while anchorage-independent growth and tumor
formation can occur in the absence of OPN, these phenotypes, in
particular tumor formation in vivo, are substantially enhanced in
wildtype, OPN-expressing cells as compared to OPN deficient
ones. Thus, OPN is required for full expression of the transformed
phenotype.
MATERIALS AND METHODS
Preparation and immortalization of mouse embryo
fibroblasts
Mouse embryo fibroblast (MEF) cells were prepared as described
(Rittling, 1996). Briefly, mouse embryos were removed from the
uterus of 12–16-day pregnant mice, minced finely with scissors
and digested with 0.125% trypsin. The cells obtained were plated
on 150 mm tissue culture dishes at a density of 1 ´ 107 in DMEM
(Gibco, Grand Island NY, USA) supplemented with 10% FBS
(Gemini Bio-Products, Calabasas, CA, USA). For the first and
second passages, cells were plated on 100 mm tissue culture
dishes at a density of 1 ´ 106; in later passages, cells were plated at
3T3 density (8 ´ 105) on 100 mm dishes. For immortalization,
cells were passed every three days and plated at 8 ´ 105 on 
100 mm dishes (Rittling, 1996). The numbers of cells plated (No),
and the numbers of cells after three days of growth (N) were
recorded, and the ratio (N/No) was calculated as a growth-rate
indicator. Cells were considered to be immortalized when the ratio
N/No became higher than 3.0.
Mice
Wildtype and OPN-deficient mice were housed and bred sepa-
rately under specific pathogen-free conditions as described
(Rittling et al, 1998). Embryos were obtained from homozygous
females, either wildtype or OPN-deficient, that had been mated to
males of the same genotype. Mice used for embryo collection were
in the 129 ´ C57BL/6 F2 genetic background.
Tetracycline-inducible cell lines
OPN-deficient 3T3 cells were transfected sequentially with pTet-
Off (pUHD-15-1) (Gossen and Bujard, 1992), and with OPN
under the control of the Tet operator, and the clones expressing
the highest level of OPN selected for further analysis. The
resulting clonal lines were transfected with pSV-Ha-ras, and foci
were picked. Transformed cells from these foci were plated in soft
agar at 105 cells per 35 mm well, in the presence or absence of 
2 mg ml–1 tetracycline.
Transfection and selection
Plasmid DNA (pSV-Ha-ras: 20 mg per 100 mm dish, 10 mg per 60
mm dish) was introduced into cells by the calcium phosphate
precipitation method, followed by glycerol shock (Malyankar et
al, 1994). Foci, identified as clumps of piled-up cells against a
background monolayer, were picked after incubation for 2 weeks
with medium containing 3% or 1% FBS, to select for cells with
reduced growth factor requirements. Transfection efficiency was
assessed by cotransfection with a b-galactosidase expression
construct.
Growth curves
Cells were plated in 12-well dishes at 2.7 ´ 104 cells per well. Each
day for 6 days, cells were removed from triplicate wells and
counted, and the results plotted. Cell number at 3 days after
plating, towards the end of the exponential growth phase, is
reported.
Northern and western blotting
RNA preparation, analysis, and probes were as described (Rittling
and Novick, 1997). Western blotting for OPN was as in (Rittling 
et al, 1998b) and (Rittling and Feng, 1998), using antiserum 732,
developed in the OPN-deficient mice against mouse osteopontin
(Kowalski et al, unpublished). For quantification of ras protein
levels, cells were scraped into RIPA buffer with protein inhibitors,
and the protein concentration determined. Equal amounts of
protein (25–35 mg) were separated on 12% SDS-PAGE and
blotted. The blots were reacted with anti-H-ras antibody F235
(Santa Cruz Biotechnology, non-cross reactive with N-ras and 
K-ras) at 1 mg ml–1.
Colony formation in soft agar
Anchorage-independent growth assays were performed using 6-
well plates (Freedman and Shin, 1974). Experiments were done in
triplicate. Each well was coated with 2 ml of a base layer
containing 0.6% agar, 1 ´ DMEM, 10% FBS. Subconfluent cells
were collected in 10 ml of medium, counted and suspended in
DMEM containing 10% FBS, 0.3% agar and 1 ml of the mixture
containing 104 cells was plated over the 2 ml base layer in each
well (three wells total for each cell line). After 14 days incubation
with twice-a-week feeding (1 ml each time per dish of DMEM,
0.3% agar and 10% FBS), colonies (consisting of about 20 cells or
more) in 10 high-power fields per dish were counted, and total
colonies per dish calculated.
Tumor formation
Subconfluent, rapidly growing cells were collected and suspended
in PBS at 1 ´ 106 cells per ml, and 0.5 ml of this cell suspension
was injected subcutaneously in the upper dorsal region of 3–4
syngeneic (129 ´ C57Bl/6 F1, wildtype) and/or nude mice. Tumor
size was measured with calipers every second day until the tumors
reached 20% of the weight of the animal. Tumor volume was
calculated according to the following formula: 4/3p (l-1) (w-1)2,
the volume of an oblate ellipse, where l is the long dimension of
the tumor, and w is the width, or short dimension, in mm; 1 mm
was subtracted from each measurement to compensate for the158 Y Wu et al
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thickness of the skin. In cases where results from only two mice
are shown, a third animal in the experiment was sacrificed prior to
20 days, usually because the tumor had grown beyond 20% of the
weight of the animal. For metastasis, 105 cells in 0.1 ml of PBS
were injected via the lateral tail vein of syngeneic F1 mice, and the
mice were sacrificed after 4 weeks. Lungs were excised, fixed and
cut into 1–2 mm slices prior to embedding. Several lung slices
were embedded in a single block, and tumor size in the resultant
H+E stained sections determined by measurement of the projected
image. Mice were housed in microisolator cages in an AALAC-
approved animal facility, and all procedures were approved by the
Rutgers University Institutional Review Board – Animal Care and
Facilities Committee.
RESULTS
Establishment of immortal and transformed cell lines
Primary embryo fibroblasts were prepared from 13–15-day preg-
nant females. Initial experiments in which these primary cells were
transfected with a mutant ras construct together with an activated
p53 construct indicated that in both wildtype and OPN-deficient
mice, the rate of focus formation was too low to be useful.
Therefore, spontaneously immortalized cell lines were derived by
continuous passage according to the 3T3 protocol. Three indepen-
dent mouse embryo fibroblast (MEF) cultures from both wildtype
and OPN-deficient mice were obtained, and passed to obtain
immortal cell lines. While there is considerable variability in the
rate at which different cell lines pass through crisis (Rittling,
1996), there was no consistent difference between the wildtype
and OPN-deficient cells (Figure 1), nor was there any consistent
difference in the average growth rate of the wildtype and OPN-
deficient cell lines (data not shown). Previous work has shown that
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Figure 1 Immortalization rate of the MEFs derived from wildtype and
OPN-deficient mice. Shown is the cumulative cell number in the population
plotted as a function of days in culture. Closed symbols represent cells
derived from wildtype mice, and the open symbols represent cells derived
from the OPN-deficient mice. Each line represents immortalization of cells
from a single mouse.
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Figure 2 Comparison of focus-forming ability between ras-transfected
wildtype and OPN-deficient spontaneously immortalized cells. 3T3 cells were
transfected with 20 mg pSV-Ha-ras per 100 mm dish using a calcium
phosphate precipitation method. After growth at 37°C for 2 weeks in DMEM
plus 3% FBS, the cells were fixed with methanol and stained with Giemsa. 
A and B: Mock transfection; A, C, E, G: wildtype 3T3 lines; B, D, F, H:
OPN-deficient 3T3 lines. C–H represent focus formation in six independently
derived 3T3 lines.
Table 1 Focus formation in wildtype (+/+) and OPN-deficient (–/–) 
immortal cell lines after ras transfection. 3T3 cell lines were plated at 5 ´ 105
cells per 100 mm dish, and transfected with an activated ras expression
construct. Two weeks following transfection, plates were fixed and stained,
and the total foci in one representative 100 mm dish were counted.
Transfection efficiency did not vary significantly between the transfections.
Results from three independent experiments with six different 3T3 lines are
shown.
Experiment Number of foci Number of foci
(+/+) (–/–)
18 4 1 1 8
25 9 6 7
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such spontaneously derived immortal cell lines represent fairly
homogeneous populations (Rittling, 1996).
These immortal cell lines were transfected with an activated ras
construct (pSV-Ha-ras), and grown in the presence of 3%, or in
some cases 1%, fetal bovine serum for 2 weeks, to select for cells
with reduced serum requirements. Morphologically transformed
foci formed in every case with similar efficiencies (Figure 2, Table
1), and there was no apparent effect of a lack of OPN on focus
formation. The average number of foci formed was 85 ± 26.5 for
WT cell lines and 87 ± 27.2 for OPN –/– lines.
For each immortal cell line, 10–20 foci were picked, and
expanded. RNA was prepared from the resulting transformed cell
lines while they were in exponential growth 3 days after plating,
and analyzed for ras mRNA levels by northern blotting. This
screening process was undertaken to select for transformed clones
that expressed comparable levels of ras mRNA, to minimize
differences between clones due to differential expression of the
transfected ras allele. Thus, in each set of screened clones, wild-
type and OPN-deficient clones that expressed similar levels of ras
mRNA were selected and expanded for further analysis. From six
independent immortal cell lines (three of each genotype) a total of
19 wildtype and 17 OPN-deficient ras-transformed cell lines were
selected for further analysis.
OPN protein levels in the primary, immortal, and transformed
cells were monitored by western blotting of media conditioned by
the different cells. While the primary wildtype cells secrete readily
detectable OPN, the level is increased about 10-fold in the corre-
sponding immortal cells, and increased still further, another seven-
fold, after ras transfection (Figure 3). No OPN was detected in
media conditioned by OPN-deficient cells. While the increase in
OPN secretion after ras transformation was expected, and
confirms that ras is active in these transformed cells, these results
indicate that immortalization can also increase the amount of OPN
secreted by cells.
Analysis of transformation in vitro
Following selection and expansion of the ras transformed cell
lines,  ras, cathepsin L, and OPN mRNA levels were analysed and
normalized to b-actin mRNA levels. Cathepsin L expression has
been shown in some cases to be, like OPN, induced by activated
ras (Chambers et al, 1992b), and so the level of this mRNA was
used as a means of assessing ras activity in the individual cell
lines. Figure 4 illustrates these data for a single set of cell lines:
two additional sets were similarly analysed. Following normaliza-
tion to b-actin mRNA levels, neither ras nor cathepsin L mRNA
levels were found to differ significantly between the wildtype and
OPN-deficient clones.
The ability of the transformed cell lines to grow under
anchorage-independent conditions was tested by seeding 104 cells
in 35 mm wells in 0.3% agar in complete medium with 10% FCS.
After 2 weeks, colonies containing more than 20 cells were
counted. The OPN-deficient cells were able to form colonies in soft
agar under these conditions, and in several cell lines colonies were
formed with as high efficiency as the wildtype cell lines (Figure 4),
and the morphology of the colonies was similar (data not shown).
However, when the number of colonies formed per 104 cells plated
was averaged over all the cell lines analyzed (19 wildtype and 17
OPN –/–), the wildtype cell lines were found to form nearly twice
as many colonies as the OPN-deficient cells (Figure 5), despite
considerable variability in the numbers of colonies formed by the
individual cell lines. To confirm this observation, ras transformed
OPN –/– cell lines were developed that expressed OPN under the
control of a tetracycline-repressible promoter (Gossen and Bujard,
1992). In these cells OPN expression is reduced about 10-fold in
the presence of tetracycline. Growth of these cells in soft agar, but
not on plastic, was reduced in the presence of tetracycline by about
20–30% (Figure 5), confirming that OPN under certain circum-
stances can facilitate anchorage-independent growth of cells.
Analysis of tumorigenesis in vivo
The ability of transformed cells to form colonies in soft agar is the
parameter that most closely correlates with tumor forming ability
in vivo (Freedman and Shin, 1974). Accordingly, the ability of
several of the wildtype and OPN-deficient cell lines to form
tumors after injection subcutaneously into mice was assessed.
Four sets of cell lines (wildtype and OPN-deficient) were selected
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Figure 3 OPN levels secreted by primary, immortal and transformed cell
lines. Media conditioned by confluent cells for 18 h were collected. 10 ml of
each medium was used in a western blot with mouse antiserum 732 directed
against mouse OPN. A representative set of cells is shown. For each set,
medium was collected from primary cells (MEF lanes), immortal cells (3T3
lanes) and transformed cells (T lanes). Similar results were obtained with two
other sets of cell lines.
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Figure 4 ras, cathepsin L, and OPN mRNA levels and colony formation in
soft agar of a series of wildtype (+/+) and OPN-deficient (–/–) transformed
cell lines. Cell lines with comparable ras levels were selected from the initial
screen and expanded. RNA was prepared after 3 days’ growth, and growth in
soft agar was determined as described in Methods. Lanes labelled PAP2 are
RNA isolated from the metastatic, ras transformed NIH 3T3 cell line PAP2
(Chambers et al, 1990). Lanes 2 and 3 (3T3) contain RNA prepared from the
parental 3T3 cells used for transfection. The same blot was probed for ras
(top panel), cathepsin L (middle panel), and OPN (lower panel). The
experiment shown is representative of three such experiments. The number
of colonies formed per 104 cells plated in soft agar for each cell line is shown
at the bottom of the figure.160 Y Wu et al
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that could form colonies efficiently in soft agar and that had
similar ras mRNA and protein levels (Figure 6, Table 2). These
cells were collected, resuspended in PBS and injected 
subcutaneously into nude or syngeneic mice. The mice used for
these injections were wildtype as there are at present no 
syngeneic OPN-deficient hosts for these 129 ´ C57Bl/6 F2 cells.
Every second day after the tumors became palpable, the tumor size
was measured with calipers. In every case the wildtype cells
formed tumors significantly earlier than did the OPN-deficient cell
lines (Figure 7) despite comparable growth of the cells in 
vitro both on plastic and in soft agar (Table 2). Similar results were
obtained with both syngeneic and nude mice (Table 2). The 
main defect observed in the OPN –/– cells was in 
the lag-time before tumor formation could be detected: once the
tumors were formed, the growth rate of the OPN –/– 
and wildtype tumors was similar (Figure 7). Thus OPN is 
required for efficient initiation of tumor growth in vivo in 
this system.
One pair of these cell lines was tested for the ability to form
metastases in lungs following intravenous injection into syngeneic
mice. The OPN-deficient cells were found to form fewer metastases,
(5.5 ± 1.8 metastases per lung section for wt vs 1.2 ± 1.0 for OPN
–/– cells; n = 3, P < 0.05), and those metastases were much smaller
than those formed by WT cells (the mean cross-sectional area of the
largest metastatic tumor examined in each section was 0.79 ± 0.42
mm2 for wt and 0.162 ± 0.16 mm2 for OPN –/– (n = 9; P < 0.01)).
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Figure 5 Colony-forming ability in soft agar of wildtype and OPN-deficient
ras-transformed cell lines, and in cells with a tetracycline-responsive OPN
construct, grown with and without tetracycline. +/+ = average colony
formation per 104 cells of 19 wildtype cell lines; –/– = average colony
formation per 104 cells of 15 OPN-deficient cells; –Tet = colony formation of
105 OPNTet cells in the absence of Tet (expressing OPN); +Tet = colony
formation of 105 OPNTet cells in the presence of Tet (reduced OPN
expression). Shown is the mean +/– SEM, P < 0.05.
2
7
9
-
3
-
7
,
 
+
/
+
2
7
7
-
3
-
4
,
 
–
/
–
2
7
9
-
3
-
1
2
,
 
+
/
+
2
4
7
-
3
-
1
2
,
 
–
/
–
2
7
5
-
1
-
4
,
 
+
/
+
2
7
7
-
1
-
1
1
,
 
–
/
–
2
7
5
-
3
-
2
,
 
+
/
+
2
4
7
-
3
-
8
,
 
–
/
–
ras
Figure 6 ras protein level in wildtype and OPN-deficient cells used for
tumour formation. Cell lysates were prepared from each cell line shown in
Table 2, and equal amounts of protein separated on 12% SDS Page gels.
Ras protein was detected with antibody F235. The designation and genotype
of each cell line is shown above the lanes. Cell line 275-1-4 expresses very
low levels of ras, and may be derived from spontaneously transformed cells.
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Figure 7 Growth of tumours in nude mice after injection of wildtype cell line
279-3-7 (solid symbols) or OPN-deficient cell line 247-3-8 (open symbols). 5
´ 105 cells in PBS were injected subcutaneously into the dorsal area of 3–4
mice. Tumour size was measured every other day, and tumour volume
calculated as described in Methods. Each line represents results from a
single mouse. Results for a representative pair of cell lines are shown – other
cell lines gave similar results, as shown in Table 2.
Table 2 Growth characteristics and tumour formation of different cell lines with high efficiency of growth in soft agar. The indicated cell lines were injected
subcutaneously into mice. At the same passage, the growth rate of the cells on plastic and in soft agar was measured.
Growth on Growth in Tumour size Tumour size
Cell line Genotype plastic ´ 105a agarb (syngeneic)c n (nude)c mm3
mm3 n
279–3–7 +/+ 4.5 ± 0.1 772 ± 64 3848,2636 2 2576 ± 667* 3
279–3–12 +/+ 3.1 ± 0.4 793 ± 110 2354,3203 2 2851 ± 758* 3
275–3–2 +/+ 6.5 ± 0.5 753 ± 70 1206 ± 237* 3 2946,5535 2
275–1–4 +/+ 1.6 ± 0.2 628 ± 35 1151 ± 778* 3 nd
247–3–8 –/– 2.2 ± 0.0 955 ± 203 137 ± 106 3 287 ± 156* 3
247–3–12 –/– 1.9 ± 0.3 1342 ± 239 335,264 2 673 ± 489* 3
277–3–4 –/– 4.6 ± 0.0 810 ± 122 46 ± 64* 3 372 ± 253 4
277–1–11 –/– 2.8 ± 0.4 1502 ± 343 44 ± 32* 3 nd
a Growth curves were constructed for each cell line as described in Methods. Total cell number per well at 3 days, when the cells were still in exponential
growth, is reported. Numbers represent the average of three determinations ± SD. b104 cells were plated in 0.3% agar, and the total number of colonies present
at 14 days determined. Numbers represent the average of three determinations ± SD. c5 ´ 105 cells were injected subcutaneously into mice, and tumour size
determined after 20 (*) or 21 days. The average total tumour size ± SD for three or four mice is shown, n represents the number of mice used. Where n = 2,
results from individual animals are shown.Osteopontin is required for maximal transformation 161
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DISCUSSION
The development of mice deficient for osteopontin expression
(Rittling et al, 1998; Liaw et al, 1998) has provided a unique
system in which to compare directly the transformed properties of
otherwise very similar cells in the presence and absence of osteo-
pontin expression. The work presented here is important in that it
provides an uncomplicated analysis of the role of OPN in multiple
aspects of cellular transformation. Our results confirm and extend
the long-held idea that OPN is important in the transformation
process, in that the transformed phenotype was attenuated in the
absence of OPN. Thus we observed lower rates on average of
colony formation in soft agar, and dramatically reduced rates of
primary tumor and metastasis growth in syngeneic and nude mice.
The only aspect of transformation for which we did not detect a
reduction in the OPN-deficient cells was in the process of focus
formation: both the wildtype and osteopontin-deficient cells
formed foci efficiently after ras transformation. This phenotype,
focus formation, most likely represents a loss of contact inhibition
of growth resulting from the expression of oncogenic ras, and we
conclude that OPN, and by deduction also the integrins to which
OPN binds in these cells, do not play a major role in this process.
We also did not detect an effect of osteopontin on the process of
spontaneous immortalization. This process requires an alteration
in the cells, probably a mutation (Rittling, 1996) that enables the
cells to overcome the growth restraints of senescence.
Our results indicate that the effects of OPN expression on
anchorage-independent growth are complex. While antisense
experiments suggested that OPN was necessary for the formation
of colonies in soft agar (Su et al, 1995; Gardner et al, 1994), we
clearly show here that OPN-deficient cell lines can form colonies
efficiently in soft agar, indicating that OPN is not absolutely
required for this process in ras-transformed cells. However, our
data show that OPN can enhance anchorage-independent growth.
Thus, OPN is not strictly required for anchorage-independent
growth, but can enhance such growth in some cell lines.
Anchorage-independent growth in ras-transformed cells probably
results from stimulation by activated ras of signaling pathways
that mediate both growth factor and integrin-initiated signals
(reviewed in Schwartz, 1997). For example, MAPK activation by
growth factors in normal cells requires adhesion through integrins
(Renshaw et al, 1997), while oncogenic ras stimulates MAPK
independently of both growth factor and integrin ligation to allow
anchorage-independent growth. The binding of soluble OPN to
integrins such as the avb3 may stimulate the signal throughput of
these pathways, even in the presence of activated ras, thereby
enhancing anchorage-independent growth, much as transformed
cells that are growth factor independent show higher rates of
growth in the presence of growth factors.
The most pronounced effect of a lack of OPN that we observed
was in the ability of the OPN-deficient transformed cells to form
tumors. For these experiments, a subset of ras-transformed cell
lines was selected that had similar ras levels and formed colonies
efficiently in soft agar. While the OPN-deficient clones were able
to form tumors in syngeneic or nude mice, they did so at a substan-
tially slower rate than the wildtype cells. Thus, OPN clearly can
enhance tumor formation in vivo. It is important to note here that
the recipients for these tumor cell injections were wildtype mice,
so OPN could have been produced by the stromal cells in the
vicinity of the injection of the OPN-deficient cells. Thus host-
derived OPN may have contributed to the ultimate ability of the
OPN-deficient cells to form tumors. Indeed, we have found (Wu,
Feng and Rittling, manuscript in preparation) that tumors arising
from the OPN-deficient cells contain measurable amounts of
OPN, which may have been supplied by infiltrating macrophages
(Brown et al, 1994; Casson et al, 1997) or other sources.
We have considered several hypotheses to explain the mecha-
nism of OPN’s ability to enhance tumor formation. It is unlikely
that OPN is acting in an autocrine manner to stimulate growth of
the tumor cells themselves since these cells already show efficient
anchorage-independent growth. Alternatively, high level OPN
expression could protect cells from apoptosis in the first few days
following tumor cell injection. A role for the OPN-binding inte-
grins a5b1 and avb3 in preventing apoptosis (or anoikis (Frisch and
Ruoslahti, 1997)) of transformed cells has previously been demon-
strated (Montgomery et al, 1994; Zhang et al, 1995). Denhardt and
Chambers (1994) have proposed that OPN, by virtue of its ability
to inhibit iNOS activity, protects tumor cells from attack by cyto-
toxic cell in vivo, and this may be a possible mechanism of action
of OPN in stimulating tumor growth. The possible conflicting role
of macrophages in OPN-dependent tumorigenesis has been
discussed recently (Crawford et al, 1998). Finally, OPN has been
shown to stimulate migration of endothelial cells (Liaw et al,
1995), particularly in association with VEGF (Senger et al, 1996).
Possibly, expression of OPN in the injected cells is required for
optimal angiogenesis. This idea is supported by the observations
that ligation of the avb3 integrin protects endothelial cells against
apoptosis (Brooks et al, 1994a; Strömblad et al, 1996) and stimu-
lates angiogenesis (Brooks et al, 1994b), and that surface-bound
OPN can protect endothelial cells from apoptosis (Scatena et al,
1998). Work is in progress to distinguish these possibilities.
Experiments with transformed cells are hampered by the well-
known heterogeneity of such cells, making it difficult to make
direct comparisons between different transformed cell lines. Our
analysis of a large number of cell lines has allowed us to develop a
consensus of the effects of OPN in vitro, despite considerable vari-
ability among individual cell lines. The results with tumor forma-
tion, however, were less variable, in that every cell line tested
showed a slower rate of tumor growth. Thus, it may be that the
effects of OPN are more pronounced in the whole animal than in
culture, possibly reflecting an important role for this protein in
mediating cellular interactions.
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